Tern extends Device Authority convertible loan note maturity date

Money and Investment

Tern Plc (LON:TERN), the investment company specialising in the Internet of Things, has announced that the maturity date for all convertible loan notes provided to Device Authority Limited by Tern, Alsop Louie Partners and the George Samenuk Family Trust et al., has been extended to 31 March 2022.  

All existing repayment and conversion rights, automatic and at the holder’s option, have also been extended to 31 March 2022.  All other terms of these loan notes remain unchanged and as previously announced.

The outstanding convertible loan balance payable by Device Authority to Tern currently stands at US$4.3 million, excluding US$0.6 million of interest accrued to date.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Pharma engagement shifts from reach to relevance

Pharma engagement is moving from broad reach to relevant messaging across connected patient journeys.

Device Authority partnership expands route into enterprise IoT security

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning by placing KeyScaler within a managed, identity-led cybersecurity model for complex and regulated environments.

Tern increases convertible loan note investment in Talking Medicines

Tern has received ÂŁ270,000 of new unsecured convertible loan notes from Talking Medicines, increasing its total convertible loan note holding to approximately ÂŁ0.79 million while retaining a 23.8% equity stake.

Tern Plc invests $280,000 in Device Authority convertible loan notes

Tern has invested $280,000 in new unsecured convertible loan notes issued by Device Authority, forming part of a wider funding round of up to $1.6 million from existing investors.

Surgical training technology moves closer to the centre of precision medicine

Fundamental XR is targeting a critical adoption gap in advanced healthcare by using immersive simulation to help surgical teams prepare for complex procedures with greater consistency and scale.

GLP-1 therapies move into a wider investor debate

GLP-1 therapies are moving beyond weight loss and diabetes, creating a wider investor discussion around behaviour, risk and market positioning.

Search